

Nasdaq Symbol

PSTV

Company

Clinical-stage pharmaceutical company with multiple oncology product candidates:

Rhenium NanoLiposome (RNL™)  
DocePLUS™  
DoxoPLUS™

Management Team

Marc Hedrick, MD, MBA  
President & Chief Executive Officer

Andrew Sims  
VP & Chief Financial Officer

Gregory Stein, MD, MBA  
SVP, Clinical Development

Cheri Rice  
VP, Product Development

Russ Havranek  
VP, Strategy & New Product Planning

Issuer

Plus Therapeutics, Inc. ("Plus" Or  
"The Company")

Audit Firm

BDO LLP

Headquarters

4200 Marathon Blvd., Suite 200  
Austin, TX 78756

Corporate Law Firm

Pillsbury Winthrop, Houston, TX

Contact Info

Andrew Sims  
(619) 333-4150  
[ir@plustherapeutics.com](mailto:ir@plustherapeutics.com)

Corporate Website[plustherapeutics.com](http://plustherapeutics.com)**Executive Summary**

- + PLUS is a NASDAQ-traded, clinical-stage pharmaceutical company based in Austin, Texas.
- + Our mission is to become the world's leader in developing better and safer nanoscale oncology drugs to improve survival and quality of life for both pediatric and adult patients.
- + We have 3 clinical-stage oncology drugs in development.
- + Our lead drug is a novel radio-liposome called RNL™ that is currently in clinical development for recurrent brain cancer and currently funded by the National Cancer Institute.
- + Our pre-clinical pipeline includes drugs for other cancers such as leptomeningeal carcinomatosis, peritoneal carcinomatosis, head and neck cancer, and others.
- + Our drug development capability is unique and based on our technology and expertise in nanoscale drug design, manufacturing, and our capabilities in radiotherapeutic and chemotherapeutic delivery.
- + Our drug development model seeks to be highly capital efficient through a virtual development model, low overhead, and leverage of non-dilutive capital whenever feasible.

**Key Academic Collaborators****Clinical Pipeline**


- + **RNL™**: A novel liposomal radiotherapeutic; lead indication is recurrent glioblastoma (rGBM). Additional preclinical development ongoing in head and neck cancer, peritoneal carcinomatosis, leptomeningeal carcinomatosis, and others.
- + **DocePLUS™**: A novel liposomal chemotherapeutic; completed U.S. Phase 1 clinical trial in 29 patients with solid tumors.
- + **DoxoPLUS™**: A novel liposomal chemotherapeutic; clinical bioequivalence demonstrated to Janssen's CAELYX® in ovarian cancer patients.

**Value Proposition for Lead Drug Candidate: RNL in rGBM**

- + **Initial Clinical Indication**: rGBM is a rare, incurable, and deadly primary malignant brain tumor, affecting 13,000 people in the U.S. with a median survival of about 9 months.
- + **RNL Market Opportunity**: In rGBM, peak annual net revenue in U.S., EU5, and Japan forecasted \$500M+.
- + **Radioactive Isotope**: Isotopic rhenium is unique dual energy 'theragnostic' isotope.
- + **Mechanism of Action**: Isotopic rhenium produces high energy beta particles lethal to cancer cells.
- + **Duration of Effect**: RNL half-life of 90 hours ensures prolonged time of therapeutic on the tumor and liposome technology facilitates RNL retention within the brain tumor.
- + **Highly Targeted Therapy**: Computerized planning and stereotactic delivery targets RNL directly to the brain tumor only.
- + **Dosing**: Potential for radiation doses 25 times higher than typical external beam radiation.
- + **Prognostic Accuracy**: Isotopic rhenium gamma energy provides for real-time imaging, accurate dosimetry and, therefore, potential for prognostic information.
- + **Patient Convenience**: RNL requires a single treatment visit vs. approximately 20 treatment visits required for standard fractionated external beam radiation.
- + **Safety**: RNL exerts selective effect on cancer cells, potentially sparing normal brain tissue.

RNL for rGBM – ReSPECT™ Phase 1 Trial

- + ReSPECT is a multi-center, open-label, volume and dose finding study of the safety, tolerability, and distribution of <sup>186</sup>RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment.
- + **Trial status:** Completed 5 dosing cohorts and 15 patients treated thus far.
- + **Safety:** Well-tolerated with no dose-limiting toxicities.
- + **Efficacy Signals:** Early efficacy signals in patients with adequate tumor coverage (2 patients survived > 30 months).
- + **External Grant Support:** RNL clinical development supported by over \$3M grant from National Cancer Institute.
- + **Enrollment Plan:** ReSPECT is actively enrolling rGBM patients at two cancer centers, one more site planned for 2020.
- + **Regulatory:** Seeking U.S. & E.U. Orphan Drug Designations and U.S. Fast Track Designation in 2020.



SPECT scan demonstrates high dose radiation delivered by RNL throughout the tumor that persists for at least 8 days.

RNL Development Plan

RNL Development	2020	2021	2022	2023	2024
rGBM	Active Phase I Trial	Anticipated Phase II/Pivotal Trial			
Leptomeningeal Cancer	Preclinical				
Peritoneal Cancer	Preclinical				
Head & Neck Cancer	Preclinical				

Forthcoming Milestones

- + Complete enrollment and report preliminary data from ReSPECT Phase I clinical trial.
- + Align with FDA on Phase 2/pivotal trial plan for RNL in recurrent glioblastoma.
- + Complete IND-enabling studies for additional indications.
- + FDA & EU feedback on Orphan Drug Designation applications.
- + FDA feedback on Fast Track Designation application.
- + Potential partnerships related to 3 clinical-stage assets.

Capitalization Summary (select data as of June 30, 2020)

- + Cash \$9.3M.
- + Common shares outstanding 4,273,857.
- + Series U Warrants 3,362,500.
- + Senior Term Loan principal of \$4.3M.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this document that is not a historical fact is a “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.

Risks and uncertainties for Plus include, but are not limited to: an inability or delay in obtaining required regulatory approvals for product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; failure to realize any value of certain product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approval by the FDA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for the combined company’s products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third-party manufacturers or establish commercial scale manufacturing capabilities; loss of or diminished demand from one or more key customers or distributors; unexpected cost increases and pricing pressures; economic recession and its negative impact on customers, vendors or suppliers; uncertainties of cash flows, expenses and inability to meet working capital needs; and other risks and uncertainties detailed in the risk factors section of Plus’ Form 10-K and Forms 10-Q filed with the SEC, as well as other filings Plus makes with the SEC from time-to-time. Many of these factors that will determine actual results are beyond Plus’ ability to control or predict. Plus disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.